01 Dedicated Contrast Delivery Systems Moving Into Clinical CEUS Workflows The need for more consistent contrast administration is bringing dedicated delivery systems into the Contrast-Enhanced Ultrasound Market. This transition is moving CEUS workflows beyond manual injection toward standardized delivery, with Bracco’s VueJect receiving U.S. FDA 510(k) clearance on August 3, 2026, under device number K262115 and Health Canada Medical Device License No. 115637. VueJect also enables continuous administration of ultrasound contrast agents during cardiac imaging, helping reduce operator variability and support more consistent enhancement across examinations.
02 CEUS Expanding Beyond Traditional Liver and Cardiac Imaging The ability of CEUS to provide real-time microvascular perfusion information without ionizing radiation is extending its use into breast and other superficial-organ imaging applications. This shift is becoming more clinically structured, with a 2026 breast CEUS consensus developed by an expert panel comprising 52 listed authors and covering acquisition methods, qualitative and quantitative enhancement analysis, interpretation, and standardized reporting. The same consensus notes that breast CEUS has already been used in clinical practice for nearly two decades, showing that broader applications are moving from experimental use toward more formalized diagnostic workflows.
01 Radiation-Free Imaging Demand and Cost-Effective Diagnostics Drive Market Growth Higher clinical preference for radiation-free imaging supports CEUS demand because ultrasound does not use ionizing radiation, unlike CT-based examinations. A clinical study of 146 focal liver lesions found that CEUS alone classified 89.0% as benign or malignant and provided specific lesion identification in 80.8% of cases. Repeated liver-lesion surveillance and follow-up imaging therefore provide practical applications where CEUS can reduce reliance on additional CT examinations and associated radiation exposure. Broader use of radiation-free diagnostic pathways consequently strengthens demand for ultrasound contrast agents, CEUS-capable systems, and related imaging services.Greater pressure to control diagnostic costs increases interest in CEUS when clinicians can characterize lesions without immediately moving patients to CT or MRI. A multicenter study covering 575 focal liver lesions found that CEUS correctly differentiated benign from malignant lesions in 97.2% of cases and generated savings of about €162 per patient for the national health service compared with the conventional diagnostic pathway. Another prospective study of 459 patients found CEUS-based evaluation costs were about 4% lower than CT and substantially lower than MRI for incidental focal liver lesions.
01 Limited Contrast Agent Approvals and Low Clinical Awareness Restrain Market Expansion Limited approval of ultrasound contrast agents across countries and clinical indications restricts where CEUS can be routinely used. Hospitals may avoid expanding CEUS programs when approved agents, reimbursement pathways, or indication-specific guidance remain unavailable. This regulatory and availability gap slows clinical adoption and limits broader expansion of the contrast enhanced ultrasound market.Limited familiarity with contrast administration, image acquisition, and CEUS interpretation reduces confidence among clinicians who primarily rely on CT, MRI, or conventional ultrasound. Hospitals may need additional training, protocol development, and multidisciplinary coordination before CEUS becomes part of routine diagnostic workflows. This knowledge gap delays implementation and restricts adoption outside experienced imaging centers.
01 AI-Assisted CEUS Quantification and Theranostic Applications Create New Growth Opportunities Ultrasound manufacturers, imaging-software developers, and contrast-agent companies can benefit from automated perfusion analysis, lesion quantification, and standardized CEUS reporting. Bracco’s VueBox already quantifies parameters such as wash-in rate, peak enhancement, rise time, time-to-peak, and area-under-the-curve from DCE-US clips, while its current platform supports cross-platform analysis through calibration files for major ultrasound systems. Contrast-agent developers, biotechnology companies, pharmaceutical firms, and ultrasound manufacturers can benefit as microbubbles move beyond imaging toward targeted therapeutic delivery. A 2026 clinical trial evaluated ultrasound combined with microbubbles in invasive breast cancer, while another 2026 study used FDA-approved microbubbles with a clinical ultrasound scanner to investigate enhanced drug delivery in hepatocellular carcinoma.
01 Reimbursement and Cost Pressures and Complex Clinical Workflows Hinders Growth CEUS providers must account for contrast agents, compatible imaging software, and the staff time needed to complete each examination. Payment may not cover these costs consistently across care settings, making hospitals cautious about expanding CEUS services. The resulting uncertainty can slow equipment purchases and limit demand for suppliers. The 2026 U.S. Medicare outpatient payment for certain noncardiac CEUS procedures rose to $243.77, illustrating how reimbursement levels remain a practical consideration for providers.CEUS requires intravenous access, timed image capture, and coordination between imaging and clinical staff. These steps can make appointments harder to schedule and reduce the number of examinations a department can perform each day. Companies may therefore face longer sales cycles as hospitals assess whether they have enough staff and capacity to run a CEUS service. A published liver CEUS implementation report noted that examinations required two people and additional scheduling time.
March 2026 Bracco Imaging and Canon Medical Systems Europe announced a strategic collaboration at ECR 2026 by co-hosting a scientific symposium focused on advancing Contrast-Enhanced Ultrasound (CEUS), highlighting innovations to improve diagnostic efficiency, radiology workflows, and clinical adoption.
November 2025 Canon Medical Systems received U.S. FDA 510(k) clearance for Version 9.0 of its Aplio i-series ultrasound systems, introducing advanced imaging technologies that enhance image quality and workflow efficiency for ultrasound applications, including CEUS.
September 2025 Philips, GE HealthCare, and Samsung Medison showcased advanced Contrast-Enhanced Ultrasound technologies at the Korean Congress of Radiology, highlighting microvascular imaging and improved lesion characterization.